2022-11-19
On October 24th the company has signed a framework agreement with Clinmark, an international CRO, defining the principles of comprehensive cooperation in the execution of clinical trials.
Additionaly with the framework agreement, the companies have entered into an order to conduct a phase 1/2 clinical trial in primary progressive multiple sclerosis (PPMS).
PolTREG is moving significantly closer to the start of a series of planned clinical trials using TREGs innovative cell therapy.
2024-11-14
PolTREG received a new patent from China for anti-gen specific Tregs cellular therapy
2024-09-26
PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases
2024-09-16
China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis
2024-09-09
PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence
2024-07-24
The European Medicines Agency has granted PolTREG preliminary approval to launch a new Phase 2 clinical trial in presymptomatic Type-1 Diabetes.
